Warburg puts up $300M to launch a buyout-hungry drug firm

Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets. Headquartered in New York, Vertice is getting off the ground with plans to acquire branded and generic products, piecing together a scalable business in the process. Former Endo Pharmaceuticals ($ENDP) Chief Operating Officer Don DeGolyer is on board as CEO, joined by Auxilium Pharmaceuticals veteran Andrew Saik in the chief financial officer role. The company's first move was acquiring generics manufacturer VistaPharm for an undisclosed sum, establishing a production base for its future endeavors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.